The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?

Journal of Alzheimer's Disease : JAD
Ratan V BhatAnna K Sundgren-Andersson

Abstract

Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes, Alzheimer's disease (AD), bipolar disorders and cancer have been futile. Since its initial discovery in 1980 and subsequent decades of research, one cannot underscore the importance of the target and the promise of a game changing disease modifier. Several pharmaceutical companies, biotech companies, and academic institutions raged in a quest to unravel the biology and discover potent and selective GSK3 inhibitors, some of which went through clinical trials. However, the conundrum of what happened to the fate of the AstraZeneca's GSK3 inhibitors and the undertaking to find a therapeutic that could control glycogen metabolism and aberrant tau hyperphosphorylation in the brain, and rescue synaptic dysfunction has largely been untold. AstraZeneca was in the forefront of GSK3 drug discovery research with six GSK3 drug candidates, one of which progressed up to Phase II clinical trials in the quest to untangle the tau hypothesis for AD. Analysis of key toxicity issues, serendipitous findings and efficacy, and biomarker considerations in relation to safety...Continue Reading

References

Dec 17, 1998·Trends in Cell Biology·E M Mandelkow, E Mandelkow
Sep 28, 1999·Journal of Neuropathology and Experimental Neurology·J J PeiR F Cowburn
Jul 27, 2000·Annals of the New York Academy of Sciences·G W Van HoesenR Thangavel
Jul 12, 2002·Annals of Neurology·R M Damian HolsingerGeneviève Evin
May 23, 2003·Nature·Christopher J PhielPeter S Klein
Aug 2, 2003·The Journal of Biological Chemistry·Alessandra FerrariJürgen Götz
Aug 21, 2003·The Journal of Biological Chemistry·Ratan BhatJesús Avila
Dec 4, 2003·Neurobiology of Aging·Paul D Coleman, Pamela J Yao
Jun 3, 2004·Nature Reviews. Drug Discovery·Philip Cohen, Michel Goedert
Jun 11, 2004·Journal of Neurochemistry·Ratan V BhatJesús Avila
Jul 27, 2004·Protein Science : a Publication of the Protein Society·Natarajan Kannan, Andrew F Neuwald
May 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Wendy NobleKaren Duff
May 4, 2006·The Journal of Clinical Investigation·Venkatesh KrishnanOrmond A Macdougald
Aug 1, 2006·Lancet·Kaj BlennowHenrik Zetterberg
Jan 24, 2007·The European Journal of Neuroscience·Claudie HooperSimon Lovestone
Jun 26, 2007·Cells, Tissues, Organs·Bradley W Doble, James R Woodgett
Dec 20, 2007·Journal of Neurochemistry·Claudie HooperSimon Lovestone
Apr 14, 2009·The Journal of Clinical Investigation·Dominik PaquetChristian Haass
Oct 2, 2009·Nature Reviews. Drug Discovery·Kurt R BrundenVirginia M-Y Lee
Apr 28, 2010·Expert Review of Neurotherapeutics·Jesús AvilaFélix Hernández
Feb 4, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Olivia A ShiptonMariana Vargas-Caballero
Dec 14, 2011·Nature·Tomasz JaworskiFred Van Leuven
Mar 13, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Sep 1, 2012·Journal of Alzheimer's Disease : JAD·Teodoro del SerTeresa León
Dec 4, 2012·The Journal of Clinical Investigation·Philip T T LyWeihong Song
Oct 27, 2015·Nature Communications·Weijun ShenBryan Laffitte
Apr 21, 2016·ChemMedChem·Xueshi HaoTom Y-H Wu

❮ Previous
Next ❯

Citations

Apr 2, 2020·Cells·Leonie HoffmeisterRené Huber
May 21, 2020·Frontiers in Cellular Neuroscience·Razia SultanaOlalekan M Ogundele
Jul 9, 2020·Molecular Psychiatry·Stephen J HaggartyRoy H Perlis
Jul 1, 2020·Neural Regeneration Research·Wen-Yuan TaoXiao-Lei Zhu
Jan 2, 2020·International Journal of Molecular Sciences·Tao ZhangTae Ho Lee
Oct 24, 2020·ELife·İbrahim Avşar IlikTuğçe Aktaş
Feb 3, 2021·Cells·Melinda E SnitowPeter S Klein
Dec 20, 2020·Biomolecules·Octavio Silva-GarcíaVíctor M Baizabal-Aguirre
Apr 9, 2021·Acta Neuropathologica·Jaime Vaquer-AliceaLukasz A Joachimiak
Feb 2, 2020·Biochimica Et Biophysica Acta. Molecular Cell Research·Elisabetta LaurettiDomenico Praticò
Jun 26, 2020·The Journal of Thoracic and Cardiovascular Surgery·David S Schrump, Chuong D Hoang
Aug 14, 2021·Cell Stress & Chaperones·Elham RazaniDavood Bashash
Aug 19, 2021·The Journal of Physical Chemistry. B·David J ReilleyAnastassia N Alexandrova
Oct 29, 2020·ACS Omega·Patricia A VignauxSean Ekins
Jun 12, 2020·Biochimica Et Biophysica Acta. Molecular Cell Research·Mohammad A AlfhiliShaw M Akula
Jun 25, 2020·Developmental Neuroscience·Amita ShresthaOlalekan M Ogundele

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.